Scarica l'app Stockscreener
11.94
7.09%
0.79
Dopo l'orario di chiusura:
11.90
-0.04
-0.34%
Precedente Chiudi:
$11.15
Aprire:
$11.24
Volume 24 ore:
215.06K
Relative Volume:
2.71
Capitalizzazione di mercato:
$316.71M
Reddito:
-
Utile/perdita netta:
$-29.59M
Rapporto P/E:
-9.3647
EPS:
-1.275
Flusso di cassa netto:
$-18.35M
1 W Prestazione:
+21.84%
1M Prestazione:
+8.15%
6M Prestazione:
+55.27%
1 anno Prestazione:
+38.19%
Intervallo 1D:
$11.14
$12.08
Intervallo di 1 settimana:
$9.67
$12.08
Portata 52W:
$5.55
$13.34
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Nome
Nuvectis Pharma Inc
Settore
Industria
Telefono
360-837-7232
Indirizzo
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
11.94 | 295.76M | 0 | -29.59M | -18.35M | -1.275 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-02 | Iniziato | Maxim Group | Buy |
| 2025-03-17 | Iniziato | Laidlaw | Buy |
| 2022-07-13 | Iniziato | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Borsa (NVCT) Ultime notizie
NVCT Q1 2026 Earnings: Surprise EPS Beat Signals Cost Discipline Amid Pre-Revenue StatusRevenue Per Share - newsline.com
NVCT Maintained by HC Wainwright & Co. -- Price Target Raised to $13.00 - GuruFocus
Nuvectis Shareholders Approve Director Election and Auditor Ratification - TipRanks
Nuvectis Pharma (NVCT) director granted 35,000 restricted common shares - Stock Titan
Nuvectis Pharma (NVCT) director awarded 35,000 restricted shares, now holds 122,828 - Stock Titan
Nuvectis Pharma (NVCT) grants director Juan Sanchez 35,000 restricted shares - Stock Titan
Nuvectis Pharma (NVCT) director awarded 35,000 restricted common shares in Form 4 filing - Stock Titan
[8-K] Nuvectis Pharma, Inc. Reports Material Event - Stock Titan
Nuvectis Pharma price target raised to $13 from $10 at H.C. Wainwright - TipRanks
NVCT Q1 2026 Earnings: Narrower-Than-Expected Loss Reinforces Cost DisciplinePost-Earnings Reaction - newsline.com
Nuvectis Pharma (NVCT) Rallies 1.94% as Stock Tests Key Resistance at $11.04Long Short Pair - newsline.com
Analyst Reiterates Buy on Nuvectis Pharma, Maintains $17 Price Target on NXP900 Pipeline Upside and Favorable M&A Read‑Through - TipRanks
(NVCT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
NVCT Q1 2026 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Biotech Advances PipelineProfit Inflection Point - newsline.com
NVCT Q1 2026 Earnings: EPS Beat Despite No Revenue, Stock DeclinesEarnings Yield Analysis - newsline.com
Responsive Playbooks and the NVCT Inflection - Stock Traders Daily
NVCT Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline AdvancesSlow Growth Warning - The Legal Advocate
Nuvectis Pharma (NVCT) Declines 5.39% as Stock Tests Key Support LevelIchimoku Cloud - thelegaladvocate.com
Wall Street analysts think Nuvectis Pharma (NVCT) could surge 57%: Read this before placing a bet - MSN
Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet - sharewise.com
NVCT Q1 2026 Earnings: Better-than-Expected Loss Narrower as Company Advances PipelineRevenue Growth Outlook - newsline.com
Nuvectis Pharma (NVCT) Surges +2.82%, Nearing $11.48 Resistance 2026-05-21IV Contraction - Newser
Understanding the Setup: (NVCT) and Scalable Risk - Stock Traders Daily
NVCT Stock Price, Quote & Chart | NUVECTIS PHARMA INC (NASDAQ:NVCT) - ChartMill
Nuvectis Pharma set to participate in key investor event at NASDAQ - Traders Union
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - The Manila Times
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor ... - Caledonian Record
Number of shareholders of Nuvectis Pharma, Inc. – NASDAQ:NVCT - TradingView
Number of shareholders of Nuvectis Pharma, Inc. – BOATS:NVCT - TradingView
TradingKey - TradingKey
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade - MSN
Nuvectis Pharma (NVCT) price target decreased by 11.71% to 16.66 - MSN
The Technical Signals Behind (NVCT) That Institutions Follow - Stock Traders Daily
What Nuvectis Pharma (NVCT) does that creates lasting value (Creeps Higher) 2026-05-08Momentum Investing - newser.com
Analysts’ Top Healthcare Picks: Precision BioSciences (DTIL), Nuvectis Pharma (NVCT) - The Globe and Mail
Companies Like Nuvectis Pharma (NASDAQ:NVCT) Are In A Position To Invest In Growth - simplywall.st
Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Nuvectis Pharma | 10-Q: Q1 2026 Earnings Report - Moomoo
Nuvectis Pharma, Inc. Q1 2026: Net loss $(6.05M), EPS $(0.26) — 10-Q Summary - TradingView
Nuvectis Pharma (NASDAQ: NVCT) posts $6.1M Q1 loss with $25.1M cash - Stock Titan
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business HighlightsSEC.gov - SEC.gov
Nuvectis Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Nuvectis Pharma posts first quarter 2026 financial results and business update - Traders Union
Cancer drug developer targets summer data as cash drops to $25.1M - Stock Titan
Insider Stock Buying Reaches US$2.07m On Nuvectis Pharma - Yahoo Finance
NVCT (Nuvectis Pharma) posts narrow Q4 2025 EPS miss, edging down 0.23% in muted investor reaction.Open Stock Picks - newser.com
Nuvectis Pharma Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
NVCT Forecast, Price Target & Analyst Ratings | NUVECTIS PHARMA INC (NASDAQ:NVCT) - ChartMill
Nuvectis Pharma (NVCT) Stock: Technical Risk Signals | Q4 2025: Below ExpectationsCommunity Risk Signals - Newser
Nuvectis Pharma Inc Azioni (NVCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nuvectis Pharma Inc Azioni (NVCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sanchez Juan | Director |
Nov 05 '25 |
Buy |
5.79 |
13,000 |
75,270 |
78,150 |
| Kaplan Matthew L. | Director |
Nov 05 '25 |
Buy |
5.84 |
11,000 |
64,240 |
124,760 |
| Mosseri Marlio Charles | 10% Owner |
Oct 27 '25 |
Buy |
6.28 |
72,836 |
457,410 |
3,136,576 |
| Mosseri Marlio Charles | 10% Owner |
Oct 23 '25 |
Buy |
6.06 |
46,900 |
284,214 |
3,028,706 |
| Mosseri Marlio Charles | 10% Owner |
Oct 24 '25 |
Buy |
6.15 |
35,034 |
215,459 |
3,063,740 |
| Mosseri Marlio Charles | 10% Owner |
Jun 20 '25 |
Buy |
7.99 |
5,603 |
44,768 |
2,981,806 |
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):